Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer

Marcelo V Negrao ¹, Ferdinandos Skoulidis,¹ Meagan Montesio,² Katja Schulze,³ Ilze Bara,³ Vincent Shen,³ Hao Xu,³ Sylvia Hu,³ Dawen Sui,⁴ Yasir Y Elamin,¹ Xiuning Le,¹ Michael E Goldberg,² Karthikeyan Murugesan,² Chang-Jiun Wu,⁵ Jianhua Zhang,⁵ David S Barreto,⁶ Jacquelyne P Robichaux,¹ Alexandre Reuben,¹ Tina Cascone,¹ Carl M Gay,¹ Kyle G Mitchell ⁷, Lingzhi Hong,¹ Waree Rinsurongkawong,¹ Jack A Roth,⁷ Stephen G Swisher,⁷ Jack Lee ⁴, Anne Tsao,¹ Vassiliki Papadimitrakopoulou,⁸ Don L Gibbons,¹ Bonnie S Glisson,¹ Gaurav Singal,² Vincent A Miller,² Brian Alexander,² Garrett Frampton,² Lee A Albacker,² David Shames,³ Jianjun Zhang ¹, John V Heymach¹

To cite: Negrao MV, Skoulidis F, Montesio M, *et al.* Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. *Journal for ImmunoTherapy of Cancer* 2021;9:e002891. doi:10.1136/jitc-2021-002891

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/jitc-2021-002891>).

Accepted 19 July 2021

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Dr John V Heymach;
JHeymach@MDAnderson.org

Dr Jianjun Zhang;
jzhang20@mdanderson.org

ABSTRACT

Background Non-small cell lung cancer (NSCLC) patients bearing targetable oncogene alterations typically derive limited benefit from immune checkpoint blockade (ICB), which has been attributed to low tumor mutation burden (TMB) and/or PD-L1 levels. We investigated oncogene-specific differences in these markers and clinical outcome. **Methods** Three cohorts of NSCLC patients with oncogene alterations (n=4189 total) were analyzed. Two clinical cohorts of advanced NSCLC patients treated with ICB monotherapy [MD Anderson (MDACC; n=172) and Flatiron Health-Foundation Medicine Clinico-Genomic Database (CGDB; n=894 patients)] were analyzed for clinical outcome. The FMI biomarker cohort (n=4017) was used to assess the association of oncogene alterations with TMB and PD-L1 expression. **Results** High PD-L1 expression (PD-L1 ≥50%) rate was 19%–20% in classic *EGFR*, *EGFR* exon 20 and *HER2*-mutant tumors, and 34%–55% in tumors with *ALK*, *BRAF* V600E, *ROS1*, *RET*, or *MET* alterations. Compared with *KRAS*-mutant tumors, *BRAF* non-V600E group had higher TMB (9.6 vs *KRAS* 7.8 mutations/Mb, p=0.003), while all other oncogene groups had lower TMB (p<0.001). In the two clinical cohorts treated with ICB, molecular groups with *EGFR*, *HER2*, *ALK*, *ROS1*, *RET*, or *MET* alterations had short progression-free survival (PFS; 1.8–3.7 months), while *BRAF*V600E group was associated with greater clinical benefit from ICB (CGDB cohort: PFS 9.8 months vs *KRAS* 3.7 months, HR 0.66, p=0.099; MDACC cohort: response rate 62% vs *KRAS* 24%; PFS 7.4 vs *KRAS* 2.8 months, HR 0.36, p=0.026). *KRAS* G12C and non-G12C subgroups had similar clinical benefit from ICB in both cohorts. In a multivariable analysis, *BRAF*V600E mutation (HR 0.58, p=0.041), PD-L1 expression (HR 0.57, p=0.022), and high TMB (HR 0.66, p<0.001) were associated with longer PFS.

Conclusions High TMB and PD-L1 expression are predictive for benefit from ICB treatment in oncogene-driven NSCLCs. NSCLC harboring *BRAF* mutations demonstrated superior benefit from ICB that may be attributed to higher TMB and higher PD-L1 expression in these tumors. Meanwhile *EGFR* and *HER2* mutations and *ALK*, *ROS1*, *RET*, and *MET* fusions define NSCLC subsets with minimal benefit from ICB despite high PD-L1 expression in NSCLC harboring oncogene fusions. These findings indicate a TMB/PD-L1-independent impact on sensitivity to ICB for certain oncogene alterations.

INTRODUCTION

PD-1/PD-L1 immune checkpoint blockade (ICB) has revolutionized the treatment of many cancer types, including non-small cell lung cancer (NSCLC). ICB has the potential to induce durable responses; however, the response rate from single agent ICB is only 15%–20%.^{1–3} High PD-L1 expression^{4–6} and high tumor mutational burden (TMB)^{7–10} have been well documented to be associated with superior benefit from ICB in NSCLC. However, driver alterations in *EGFR* and *ALK* oncogenes have been associated with cold immune microenvironment¹¹ and poor outcomes from ICB therapy.^{1 9 12–14} More recently, a study on the IMMUNOTARGET registry demonstrated distinct patterns of responses to ICB in NSCLC patients carrying rare canonical oncogene alterations.¹⁵ These data highlighted the critical impact of oncogene alterations on response to ICB. However, due to the scarcity of these rare

oncogene-altered NSCLCs treated with ICB, the numbers of patients for certain oncogene groups were relatively small precluding definitive conclusions. Furthermore, the mechanisms underlying these distinct responses, and the impact of oncogene alterations on TMB, PD-L1 expression and on their predictive values are largely unknown, primarily due to lack of appropriate molecular and clinical data from rare oncogene-altered NSCLC patients treated with ICB.

To fill this void, we leveraged a large NSCLC cohort of 4189 patients, including 4017 NSCLC patients with oncogene alterations, TMB and PD-L1 data as well as two large registry cohorts consisting of 1066 NSCLC patients treated with ICB monotherapy to assess the impact of oncogene alterations on TMB, PD-L1 expression and clinical outcomes from ICB therapy.

METHODS

Biomarker cohort

FMI biomarker cohort

A total of 4017 NSCLC patients with molecular data including oncogene alterations, TMB and PD-L1 expression from the FMI FoundationCORE database were analyzed to assess the impact of oncogene mutations on TMB and PD-L1 (hereafter referred as FMI biomarker cohort).

Clinical cohorts

MDACC cohort

GEMINI, a MD Anderson lung cancer database was queried. A total of 172 patients with advanced NSCLC whose tumor harbored oncogene alterations (see ‘Oncogene alterations’ section) and treated with single-agent ICB (pembrolizumab, nivolumab, atezolizumab, and durvalumab) between January 2014 and May 2018 were included. Data were collected through chart review, and dataset was locked on April 5, 2019. The GEMINI database is approved by the MD Anderson Cancer Center (MDACC) Institutional Review Board (IRB), and all patients signed informed consent.

Clinico-Genomic database (CGDB) immunotherapy cohort

The Flatiron-Foundation Medicine Inc CGDB, which is a clinically annotated subset of the FMI biomarker cohort, was queried and a total of 894 patients with advanced NSCLC harboring oncogene alterations (as defined in the ‘Oncogene alterations’ section) and treated with single-agent ICB between January 2011 and December 2018 were included (hereafter referred as CGDB immunotherapy cohort).

CGDB chemotherapy cohort

To understand whether the impact of oncogene alterations was specific to ICB, we also queried the Flatiron-Foundation Medicine Inc CGDB for patients with advanced NSCLC with oncogene alterations (as defined in the ‘Oncogene alterations’ section) and treated with

combination or single-agent chemotherapy (hereafter referred as CGDB chemotherapy cohort). The study was IRB approved and included a waiver of informed consent. Data were collected from database repository, and dataset was locked on December 31, 2018.

This study was conducted in accordance with ethical guidelines including Declaration of Helsinki and US Common Rule.

Oncogene alterations

For the MDACC Cohort, genomic profiling information was obtained through Clinical Laboratory Improvement Amendments certified laboratory assay results annotated in the GEMINI database. For the CGDB and FMI biomarker cohorts, the information was obtained from respective data repositories and sequencing was performed by FoundationOne assay.

Oncogene alterations included in this study are: *BRAF*: codons 457–723, including V600E and non-V600E; *EGFR* exon 20: codons 762–823 (T790M mutation not included); *HER2*: codons 755 and 770–785; *KRAS*: codons 12, 13, 33, and 61; classic *EGFR*: exon 19 deletions and exon 21 p.L858R mutation ($\pm$ T790M mutation); *MET*: exon 14 skipping mutations; and *ALK*, *ROS1*, and *RET*: gene fusion/rearrangements.

Tumor mutational burden

For the CGDB cohorts and for the FMI biomarker cohort, TMB was determined through tissue-based next-generation sequencing (FoundationOne). TMB was defined as all mutations (including all non-synonymous and synonymous mutations with germline variants and driver mutations excluded) divided by the total covered exonic regions¹⁶ and presented as number of mutations/megabase (Mb). High TMB is defined as ≥ 10 mutations/Mb, corresponding to FMI diagnostic test definition of high TMB or ≥ 16 mutations/Mb based on OAK and POPLAR trials.¹⁷ TMB data was not available for the MDACC cohort.

PD-L1 staining

For the MDACC cohort, PD-L1 staining was obtained from pathology reports. For the CGDB cohorts, PD-L1 status was obtained from data repository. For the FMI biomarker cohort, PD-L1 staining was assessed through immunohistochemistry using the 22C3 PharmDx assay (Dako North America). PD-L1 expression was quantified by tumor proportional score (TPS) and defined as positive ($\geq 1\%$) or negative ($< 1\%$), and high ($\geq 50\%$) or low ($1\%–49\%$).^{5 6 18}

Statistical analysis

Progression-free survival (PFS) was defined as time from starting treatment until disease progression or death. Overall survival (OS) was defined as time from starting treatment until death. Patients without an event were censored at last follow-up. Left truncation method was applied to real-world PFS and OS analysis to adjust for

situations where molecular profiling occurred after the start of treatment.¹⁹

Kaplan-Meier method was used to estimate PFS and OS, and differences were assessed by log-rank test. HRs and 95% CIs were determined through Cox proportional hazards model. Multivariable analysis was performed using the Cox regression method. Best response to ICB treatment determined through RECIST V.1.1 was available only for MDACC Cohort. The *KRAS* group was used as the reference comparator because: (1) it was the most commonly mutated oncogene in these cohorts of NSCLCs; and (2) *KRAS*-mutant NSCLCs constitute a heterogeneous patient population that have been shown to have similar prognosis compared with *KRAS* wild-type patients^{20–23} and to derive similar benefit from ICB therapy when compared with *KRAS* wild-type NSCLC patients.^{1,24}

Differences in categorical variables were assessed through χ^2 or Fisher's exact test with Bonferroni method for between group comparisons. Continuous variables were tested for normality using Shapiro-Wilk test, and Dunn's test with Benjamini-Hochberg correction was used for between group comparisons. Significance was established at p value ≤ 0.05 . Statistical analysis was performed on GraphPad Prism V.7.0 (La Jolla, California, USA), IBM SPSS Statistics V.24.0 (Armonk, New York, USA), SAS (Cary, North Carolina, USA), and RStudio V.3.5.5 (Boston, Massachusetts, USA).

RESULTS

TMB and PD-L1 are associated with clinical benefit from immunotherapy in oncogene-driven NSCLC

We first analyzed the CGDB immunotherapy cohort (median follow-up 17.8 months (95% CI 15.6 to 19.8)) to assess the predictive performance of TMB or PD-L1 for benefit from ICB in oncogene-driven NSCLC. We observed that higher TMB using either 10 or 16 mut/Mb as the cut-off was associated with longer PFS (TMB ≥ 10 vs <10 mut/Mb: HR 0.61, 95% CI 0.50 to 0.75, $p < 0.001$; TMB ≥ 16 vs <16 mut/Mb: HR 0.52, 95% CI 0.39 to 0.69, $p < 0.001$), and longer OS (TMB ≥ 10 vs <10 mut/Mb: HR 0.79, 95% CI 0.64 to 0.97, $p < 0.001$; TMB ≥ 16 vs <16 mut/Mb: HR 0.69, 95% CI 0.51 to 0.92, $p < 0.001$) consistent with previous findings.^{7,8,10,17} Positive PD-L1 expression was associated with longer PFS (PD-L1 positive vs negative: HR 0.48, 95% CI 0.30 to 0.77, $p < 0.001$), but the difference did not reach statistical significance for OS (PD-L1 positive vs negative: HR 0.66, 95% CI 0.39 to 1.10, $p = 0.095$). In a multivariable analysis, higher TMB was significantly associated with longer PFS (TMB ≥ 10 vs <10 mut/Mb: HR 0.66, 95% CI 0.53 to 0.82, $p < 0.001$; TMB ≥ 16 vs <16 mut/Mb: HR 0.56, 95% CI 0.42 to 0.76, $p < 0.001$) (online supplemental table 1A,B), and longer OS (TMB ≥ 10 vs <10 mut/Mb: HR 0.76, 95% CI 0.61 to 0.96, $p = 0.019$; TMB ≥ 16 vs <16 mut/Mb: HR 0.66, 95% CI 0.49 to 0.89, $p = 0.006$) (online supplemental table 2A,B). PD-L1 expression was also associated with longer PFS

(TMB cut-off of 10: PD-L1 positive vs negative: HR 0.57, 95% CI 0.35 to 0.92, $p = 0.022$) (online supplemental table 1A).

Oncogene alterations were associated with distinct clinical outcomes from ICB therapy

We next assessed the impact of oncogene alterations on clinical outcome from ICB treatment using 1066 oncogene-altered advanced NSCLC patients ($n = 172$ from MDACC cohort: median follow-up 29.1 months (95% CI 26.2 to 33.6); and $n = 894$ from CGDB immunotherapy cohort: median follow-up 17.8 months (95% CI 15.6 to 19.8)) (online supplemental figure 1A,B). As outlined in online supplemental table 3, *BRAF* and *KRAS* groups were enriched for smokers ($p < 0.001$) in both MDACC cohort and CGDB immunotherapy cohort, while patients in the classic *EGFR* group received more prior treatment lines ($p < 0.001$) compared with other genomic groups, likely due to higher likelihood of prior exposure to TKIs ($p < 0.001$). Since *KRAS*-mutant NSCLC constituted the largest population in both MDACC cohort ($n = 87$) and CGDB immunotherapy cohort ($n = 601$) and have been previously shown to have similar prognosis compared with *KRAS* wild-type patients^{20–23} and to derive similar benefit from ICB therapy when compared with *KRAS* wild-type NSCLC patients,^{1,24} we used the *KRAS* group as the reference for outcome analysis.

In the MDACC cohort, the *BRAF* group had the longest PFS among all genomic groups (*BRAF* 7.4 vs *KRAS* 2.8 months, HR 0.36, 95% CI 0.14 to 0.88, $p = 0.026$) (figure 1A), while classic *EGFR* and *HER2* groups had the shortest PFS (1.8 and 1.9 months, respectively) (figure 1A). The same trend remained in subsequent multivariable analysis adjusting for PD-L1 expression and smoking status (TMB data were not available for MDACC cohort) ($p = 0.032$ for *BRAF* group, $p = 0.022$ for Classic *EGFR* group, and $p = 0.116$ for *HER2* group, online supplemental table 4). Compared with the *KRAS* group, OS was numerically longer in *BRAF* group, but the difference was not statistically significant (35.6 vs 16.8 months, HR 0.65, 95% CI (0.26 to 1.63), $p = 0.363$). Meanwhile patients with classic *EGFR* mutations had the shortest OS (11.3 months, 95% CI 5.8 to 16.9, HR 2.01, $p = 0.006$) (figure 1B). Similar trends were observed in a multivariable analysis adjusting for PD-L1 expression, although the difference was not significant (*BRAF* vs *KRAS*: HR 0.69, $p = 0.454$; classic *EGFR* vs *KRAS*: HR 1.49, $p = 0.263$; online supplemental table 5). Furthermore, the *BRAF* group also had highest objective response rate (ORR) (62%) among all oncogene groups (Fisher's exact test $p < 0.001$). Compared with the *KRAS* group, the common comparator, this difference was not statistically significant (62% vs 24%, $p = 0.364$) (figure 1C). Importantly, two of three patients with *BRAF* V600E mutations had recently progressed on vemurafenib and achieved durable responses at 35+ and 20+ months post treatment on ICB. There were seven patients harboring *ALK* fusion ($n = 2$), *RET* fusion ($n = 2$) or *MET* exon 14 skipping mutations ($n = 3$) in the MDACC cohort. Except for

Figure 1 Clinical outcomes for oncogene-driven non-small cell lung cancers on treatment with single-agent PD-1/PD-L1 immune checkpoint inhibitor. (A) PFS in MDACC cohort; (B) OS in MDACC cohort; (C) waterfall plot for ORR in MDACC cohort for patients with measurable disease; (D) PFS in CGDB immunotherapy cohort; (E) OS in CGDB immunotherapy cohort. *Patients harboring V600E alteration in the *BRAF* group. CGDB, Clinico-Genomic database; PFS, progression-free survival; OS, overall survival.

two patients with *MET* mutations who had stable disease, all remaining five patients had progressive disease as best response. Results for PFS, OS and ORR are summarized in [table 1](#).

Consistent with the results from the MDACC Cohort, the *BRAF* groups in the CGDB immunotherapy cohort had the longest PFS (V600E 9.8 and non-V600E 5.4 months) ([figure 1D](#) and [table 1](#)) and OS (V600E 20.8 and non-V600E 14.9 months) ([figure 1E](#) and [table 1](#)) among all genomic groups although the difference did not reach statistical difference. Meanwhile, patients with classic *EGFR* mutations had significantly shorter PFS ([figure 1D](#) and [table 1](#)). Similar to classic *EGFR* group, patients with oncogene fusions (*ALK*: n=19; *ROS1*: n=3; *RET*: n=14) had poor outcomes with a trend for shorter PFS compared with the *KRAS* group. The *MET* exon 14 mutation group (n=34) also had a short PFS of 2.7

months, but the difference was not significant compared with the *KRAS* group (HR 1.13, 95% CI 0.69 to 1.84, p=0.59) ([figure 1D](#) and [table 1](#)). In a multivariable analysis adjusting for TMB, PD-L1 expression, and smoking status, *BRAF* V600E had longer PFS compared with the *KRAS* group (TMB cut-off of 10: HR 0.58, 95% CI 0.35 to 0.98, p=0.041; TMB cut-off of 16: HR 0.63, 95% CI 0.38 to 1.05, p=0.074) (online supplemental table 1A,B).

KRAS-mutant group is the largest group in our cohorts, and we therefore assessed whether different *KRAS*-mutant alleles are associated with distinct clinical outcome from ICB treatment. As shown in online supplemental figure 2A–E, ORR and survival were similar between G12C, G12D and G12V subgroups.

To understand whether the impact of these oncogene alterations was only present on clinical outcome from ICB, we analyzed the CGDB chemotherapy cohort (n=933) for

Table 1 Clinical outcomes according to treatment group for the MDACC and CGDB immunotherapy cohorts

	MDACC cohort				CGDB immunotherapy cohort								
	BRAF	Classic EGFR	EGFR exon 20	HER2	KRAS	BRAF V600E	BRAF non-V600E	Classic EGFR	EGFR exon 20	HER2	KRAS	MET	Fusions
Survival, median (HR; 95% CI)													
PFS	7.4 (0.36; 0.14 to 0.88)*	1.81 (2.37; 1.51 to 3.72)*	2.73 (1.28; 0.80 to 2.02)	1.88 (1.83; 1.03 to 3.26)*	2.76 (reference)	9.79 (0.66; 0.40 to 1.09)	5.42 (0.83; 0.54 to 1.28)	2.46 (1.72; 2.22 to 2.43)*	3.68 (1.31; 0.86 to 1.98)	3.02 (1.40; 0.84 to 2.36)	3.71 (reference)	2.69 (1.13; 0.69 to 1.84)	2.73 (1.53; 0.96 to 2.44)
OS	35.6 (0.65; 0.26 to 1.63)	11.3 (2.01; 1.22 to 3.31)*	22.6 (0.78; 0.44 to 1.39)	16.8 (1.40; 0.73 to 2.69)	16.8 (reference)	20.83 (0.79; 0.50 to 1.24)	14.88 (0.86; 0.57 to 1.32)	6.83 (1.33; 1.84 to 1.84)	10.22 (1.19; 0.83 to 1.73)	10.81 (1.00; 0.58 to 1.75)	11.24 (reference)	12.25 (0.77; 0.47 to 1.28)	11.60 (0.84; 0.52 to 1.35)
ORR, n (%)													
Complete/partial response	5 (62)	1 (4)	2 (10)	1 (8)	17 (24)	NA	NA	NA	NA	NA	NA	NA	NA
Stable disease	2 (25)	2 (9)	5 (25)	3 (25)	15 (21)	NA	NA	NA	NA	NA	NA	NA	NA
Progressive disease	1 (12)	19 (86)	13 (65)	8 (67)	38 (54)	NA	NA	NA	NA	NA	NA	NA	NA

*p<0.05 versus KRAS. NA, not available; ORR, objective response rate; OS, overall survival; PFS, progression-free survival.

clinical outcomes on treatment with chemotherapy across the same NSCLC oncogene groups (online supplemental figure 1C, online supplemental table 6). These analyses demonstrated that the fusion group (*ALK*: n=39; *ROS1*: n=12; *RET*: n=14) had the longest OS with chemotherapy (27.2 months in fusion group vs 11.7 months in *KRAS* group, HR 0.50, 95% CI 0.34 to 0.74, p<0.001) (online supplemental figure 3A). This difference remained significant in a multivariable analysis adjusting for prior TKI therapy (HR 0.48, 95% CI 0.33 to 0.71, p<0.001). Otherwise, PFS or OS was not different between oncogene groups (online supplemental figure 3A,B).

Oncogene-driven lung cancers show distinct patterns of PD-L1 expression and TMB

We leveraged the 4017 NSCLC patients from FMI biomarker cohort to assess the impact of oncogene alterations on PD-L1 expression and TMB. High prevalence of PD-L1 positivity (TPS ≥1%) was observed in *MET* (115/145, 79.3%), *RET* (42/54, 77.8%), *BRAF* V600E (89/118, 75.4%), *ROS1* (40/55, 72.7%) and *ALK* (136/194, 70.1%) groups, and low prevalence was observed in tumors harboring *EGFR* exon 20 (75/166, 45.2%), *HER2* (50/105, 47.6%), classic *EGFR* (exon 19 deletion and exon 21 L858R) (368/732, 50.3%), and *BRAF* non-V600E (116/208, 55.8%). Compared with *KRAS*-mutant NSCLCs, *MET*-mutant tumors had higher PD-L1 positivity rate (TPS ≥1%), while *EGFR*-mutant tumors had significantly lower PD-L1 positivity rate (figure 2A) consistent with our previous findings.²⁵ Furthermore, high PD-L1 expression (TPS ≥50%) was common in tumors harboring alterations in *MET* (80/145, 55.2%), *BRAF* V600E (57/118, 48.3%), *ROS1* fusion (23/55, 41.8%) and *RET* fusion (20/54, 37.0%). Among these, tumors harboring *MET* alterations had significantly higher prevalence of high PD-L1 expression (TPS ≥50%), while classic *EGFR*, *EGFR* exon 20, and *HER2* groups had lower prevalence of high PD-L1 compared with *KRAS* group (pairwise comparison vs *KRAS* p<0.050) (figure 2B).

Compared with the *KRAS* group, TMB was higher for *BRAF* non-V600E group (9.6 mut/Mb (n=208) vs 7.8 mut/Mb (n=2240); adjusted p=0.003), while all other oncogene groups had significantly lower TMB (adjusted p<0.001). Of note, *ALK* (n=194), classic *EGFR* (n=732), *HER2* (n=105), *RET* (n=54), and *ROS1* (n=55) groups had the lowest TMB with median <3 mut/Mb (figure 2C and online supplemental table 7).

DISCUSSION

Oncogene drivers have been long known to determine the cancer biology and clinical behavior of NSCLC. In addition to the classic targetable genomic alterations such as activating *EGFR* mutations and *ALK* fusions, more and more oncogene alterations defining distinct lung cancer groups are being discovered.²⁶ In the era of immuno-oncology, emerging evidence has demonstrated the profound impact of oncogene drivers on cancer

Figure 2 Oncogene-driven non-small cell lung cancers have distinct patterns of PD-L1 expression and TMB – FMI lung cancer database. (A) PD-L1 positivity rates; (B) high PD-L1 expression rates; (C) TMB. *Adjusted $p < 0.05$ versus *KRAS* group; **adjusted $p < 0.01$ versus *KRAS* group. TMB, tumor mutational burden.

immune microenvironment^{11 27} and benefit from ICB treatment.^{13 15 28 29} However, most of these intriguing findings are based on small cohorts because of the scarcity of data on certain genomic groups of NSCLC treated with single-agent ICB.^{13 15 28 29} Furthermore, the association between oncogene drivers and established predictive markers for benefit from ICB such as PD-L1 and TMB has not been systemically studied. To fill this void, we leveraged the clinical and molecular data from over 4000 oncogene driven NSCLC patients and analyzed the association of oncogene drivers and TMB/PD-L1 expression as well as the benefit from ICB treatment.

Our study is consistent with previous reports demonstrating the impact of TMB and PD-L1 expression in clinical outcomes from ICB therapy in NSCLC but more specifically in a population of oncogene addicted NSCLC. Furthermore, *BRAF*-mutant NSCLC had high TMB and PD-L1 expression (figure 2A–C), which may make this group more sensitive to ICB therapy. These results suggest that ICB is a reasonable choice in the frontline setting for *BRAF*-mutant, PD-L1 + NSCLC given its potential to induce durable clinical benefit. It remains unclear why the outcomes reported for the *BRAF* groups in the MDACC and CGDB immunotherapy cohorts are superior when compared with two previously published cohorts of *BRAF*-mutant NSCLC treated with ICB.^{15 28} Unfortunately, the unavailability of both TMB and PD-L1 data across the four cohorts precludes more definitive conclusions. Of note, *BRAF* + *MEK* inhibition enhances immune responses in preclinical models^{30 31} and increases duration of response and PFS in combination with ICB in melanoma patients.^{32 33} Although it remains unknown if these combinations have activity in NSCLC, these findings suggest that ICB-TKI combinations could be explored in *BRAF*-mutant NSCLC.

KRAS G12C and non-G12C mutant NSCLC patients had similar clinical outcome in both analyzed immunotherapy cohorts highlighting that mutant allele was not associated with clinical outcome on treatment with ICB in *KRAS*-mutant NSCLC. These findings are consistent with prior work from our group and others

highlighting that comutations (eg, *STK11*, *KEAP1*, and *TP53*), but not specific *KRAS* alleles, were associated with distinct subgroups with differing biological phenotypes and response to immunotherapy in *KRAS*-mutant NSCLC.^{15 34–37} These results suggest that further therapeutic intervention is warranted to increase immunogenicity of *KRAS*-mutant NSCLC. The *KRAS* G12C inhibitor AMG510 resulted in a more inflamed tumor microenvironment and increased the efficacy of ICB in an immune competent mouse model.³⁸ Consequently, clinical investigation of *KRAS* G12C inhibitors and ICB combinations are ongoing.

Consistent with prior studies, our results also demonstrated that NSCLC patients harboring classic *EGFR* mutations had inferior outcomes from ICB.^{1 9 12 13 39–41} Additionally, we observed *EGFR* exon 20 and *HER2* mutations were also associated with less benefit from single-agent ICB. This could be related to low TMB and low PD-L1 expression in these tumors. However, *EGFR*-mutant NSCLC tumors have been reported to have decreased proliferating and activated CD8 + T cell infiltration,¹³ increased adenosine pathway signaling, as demonstrated by elevated expression of CD73 and adenosine A1 receptor, increased TGF- β signaling, and lower IFN- γ expression.²⁷ Furthermore, our group has shown significantly lower T cell receptor (TCR) clonality implying less reactive TCR repertoire in *EGFR*-mutant NSCLC independent of TMB.^{11 27} These findings indicate molecular mechanisms, other than low TMB, contribute to a cold immune microenvironment in *EGFR*-mutant NSCLC. Delineating these underlying mechanisms will allow development of effective immunotherapies for *EGFR*-mutant NSCLC. Contrary to *EGFR* and *HER2*, NSCLC harboring *ALK*/*ROS1*/*RET* fusions or *MET* exon 14 skipping mutations were found to have high PD-L1 expression although with low TMB. However, this did not translate to better clinical outcomes on ICB therapy as demonstrated by the short PFS and low RR in these groups. This suggests that oncogene-specific factors other than TMB and PD-L1 expression also impact clinical outcome from ICB therapy.

Figure 3 Correlation between oncogene drivers and tumor mutational burden, progression-free survival and clinical outcome on immune checkpoint blockade therapy. Dot sizes are proportional to sample size; red: high PD-L1 expression; gray: intermediate PD-L1 expression; blue: low PD-L1 expression.

As a real-world study, our study has unavoidable limitations. First, the data are not consistent across different datasets, and many important data were missing. For example, tumor measurement was not available from the CGDB cohorts, which made estimation of ORR not feasible so that we were unable to validate the ORR from the MDACC cohort. In addition, the MDACC cohort did not have TMB data available, which limited further validation of the impact of TMB in predicting ICB outcome for oncogene-driven NSCLC. Second, we focused on NSCLC patients with oncogene drivers who received single-agent ICB. How these oncogene alterations impact the response and survival from ICB in combination with chemotherapy remains to be determined in future studies. Third, although we have over 4000 patients included, the sample size was still small, particularly for patients of certain genomic groups. For example, the number of patients in the *BRAF*-mutant group in the MDACC cohort was small, and we therefore had to combine V600E and non-V600E mutations for formal analysis, which limited us to validate the findings from the CGDB immunotherapy cohort and hampered further comparisons between V600E and non-V600E groups. Fourth, in the CGDB immunotherapy cohorts, PD-L1 status was missing in 76%–92% of patients and very few patients ($n < 5$) had high TMB (≥ 10 or ≥ 16) across all oncogene groups with the exception of *KRAS* and *BRAF* non-V600E groups. This impaired our ability to analyze the predictive performance of PD-L1 or TMB in each oncogene group. Despite these limitations, our study creates a framework of groups of oncogene-driven lung cancers with distinct patterns of TMB and PD-L1 and different clinical outcomes on treatment with ICB

that can be used for treatment decision in the clinic and for clinical trial design (figure 3).

Author affiliations

¹Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

²Foundation Medicine Inc, Cambridge, Massachusetts, USA

³Genentech Inc, South San Francisco, California, USA

⁴Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

⁵Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

⁶Department of Radiology, Breast Imaging and Interventional Center, The George Washington University, Washington, DC, USA

⁷Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

⁸Pfizer Inc, New York, New York, USA

Correction notice This paper has been updated since first published to amend corresponding author details.

Contributors Conception and design: MVN, KS, IB, SH, XL, JPR, AR, JL, LAA, DS, JZ, JVH. Development of methodology: MVN, FS, MM, KS, IB, VS, HX, SH, DS, MEG, KM, C-JW, JZ, DSB, JPR, AR, TC, CMG, KGM, LH, WR, JL, LAA, DS, JZ, JVH. Acquisition of Data: MVN, FS, MM, KS, IB, VS, HX, SH, DS, YYE, XL, MEG, KM, C-JW, JZ, DSB, TC, CMG, KGM, LH, WR, GS, VAM, BMA, GF. Analysis and interpretation of data all authors. Writing, review and or revision of the manuscript: all authors. Administrative, technical, or material support: MVN, FS, MM, KS, IB, VS, HX, SH, DS, YYE, XL, MEG, KM, C-JW, JZ, DSB, JPR, AR, TC, CMG, KGM, LH, WR, GS, JL, AST, VP, DLG, BSG, GS, VAM, BMA, GMF, LAA, DSS, JZ, JVH.

Funding The authors would like to acknowledge funding support from University of Texas MD Anderson Lung Moon Shot Program and the MD Anderson Cancer Center Support Grant P30 CA01667, NIH R01 CA190628, NIH/NCI R01 CA205150-01, Cancer Prevention & Research Institute of Texas RP160652, UT Lung SPOR P50 CA70907, Rexanna's Foundation for Fighting Lung Cancer, Bruton Endowed Chair in Tumor Biology, Standing Fund for EGFR inhibitor resistance, the Hallman fund, Fox Lung EGFR Inhibitor Fund, and The Gil and Dody Weaver Foundation (to JVH).

Competing interests MVN is a consultant for Mirati and Merck/MSD, and reports funding to the institution from Mirati, Novartis, Pfizer, Ziopharm, AstraZeneca, and Checkmate; MM is an employee of Foundation Medicine, and owns stock in Roche; KS is an employee of Genentech, and owns stock in Roche; IB is an employee of Genentech, owns stock in Roche; VS is an employee of Roche, and owns stock in Roche; HX is an employee of Roche, and owns stock in Roche; HS is an employee of Genentech, and owns stock in Roche; XL is a Consultant for Eli Lilly, AstraZeneca, and EMD Serono; MEG is a former employee of Foundation Medicine; KM is an employee of Foundation Medicine, and owns stock in Roche; JPR reports licensing/royalties from Spectrum Pharmaceuticals; TC has received speaker's fees from the Society for Immunotherapy of Cancer and Bristol-Myers Squibb, receives consulting fees from MedImmune and Bristol-Myers Squibb, and reports research funding to MD Anderson Cancer Center from Boehringer Ingelheim, MedImmune and Bristol-Myers Squibb; AT reports research grants from Eli Lilly, Millennium, Polaris, Genentech, Merck, Boehringer-Ingelheim, BMS, Ariad, Epizyme, Seattle Genetics, Takeda, and EMD Serono; advisory board member for BMS, Eli Lilly, Genentech, Roche, Novartis, Ariad, EMD Serono, Merck, Seattle Genetics, Astra-Zeneca, Boehringer-Ingelheim, Sella Life Science, Takeda, Epizyme, and Huron; VP is an employee of Pfizer; DLG reports research grants from AstraZeneca, Jenssen R & D, Takeda, Ribun Therapeutics; and honoraria member of Senofi, AstraZeneca, Ribun Therapeutics; GS is an employee of Foundation Medicine, and owns stock in Roche; VAM is an employee of Foundation Medicine, and owns stock in Roche; BA is an employee of Foundation Medicine, and owns stock in Roche; GF is an employee of Foundation Medicine, and owns stock in Roche; LAA is an employee of Foundation Medicine, and owns stock in Roche; DS is an employee of Genentech, and owns stock in Roche; JZ reports research funding from Merck, Johnson and Johnson, and consultant fees from BMS, Johnson and Johnson, AstraZeneca, Geneplus, OrigMed, Inovvent outside the submitted work; JVH reports research grants from NIH/NCI, American Cancer Society, Cancer Prevention & Research Institute of Texas, AACR Johnson & Johnson Lung Cancer, AZ, Spectrum, Checkmate Pharmaceuticals; Advisory Committees – AZ, BMS, GSK, Guardant Health, Kairos Venture Investments, BrightPath Biotherapeutics Hengrui Therapeutics, Eli Lilly, Spectrum, EMD Serono, Roche, Foundation One Medicine; Royalties & Licensing – Spectrum & Bio-Tree Systems, Inc.

Patient consent for publication Not required.

Ethics approval This study was IRB approved and conducted in accordance with ethical guidelines including Declaration of Helsinki and US Common Rule.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iDs

Marcelo V Negrao <http://orcid.org/0000-0001-8938-6699>

Kyle G Mitchell <http://orcid.org/0000-0002-4386-3258>

Jack Lee <http://orcid.org/0000-0001-5469-9214>

Jianjun Zhang <http://orcid.org/0000-0001-7872-3477>

REFERENCES

- Borghaei H, Paz-Ares L, Horn L, *et al.* Nivolumab versus docetaxel in advanced Nonsquamous Non-Small-Cell lung cancer. *N Engl J Med* 2015;373:1639-1627-39. doi:10.1056/NEJMoa1507643
- Gettinger S, Horn L, Jackman D, *et al.* Five-Year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003 study. *J Clin Oncol* 2018;36:1675-84.
- Garon EB, Hellmann MD, Rizvi NA, *et al.* Five-Year overall survival for patients with advanced Non-Small-Cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study. *J Clin Oncol* 2019;37:2518-27. doi:10.1200/JCO.19.00934
- Reck M, Rodríguez-Abreu D, Robinson AG, *et al.* Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. *N Engl J Med* 2016;375:1823-33. doi:10.1056/NEJMoa1606774
- Garon EB, Rizvi NA, Hui R. Pembrolizumab for the treatment of Non-Small-Cell lung cancer. *N Engl J Med Overseas Ed* 2015;372:2028. doi:10.1056/NEJMoa1501824
- Gandhi L, Rodríguez-Abreu D, Gadgeel S, *et al.* Pembrolizumab plus chemotherapy in metastatic Non-Small-Cell lung cancer. *N Engl J Med* 2018;378:2078-92. doi:10.1056/NEJMoa1801005
- Hellmann MD, Ciuleanu T-E, Pluzanski A, *et al.* Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. *N Engl J Med* 2018;378:2093-104. doi:10.1056/NEJMoa1801946
- Rizvi NA, Hellmann MD, Snyder A, *et al.* Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. *Science* 2015;348:124-8. doi:10.1126/science.aaa1348
- Rizvi H, Sanchez-Vega F, La K, *et al.* Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing. *J Clin Oncol* 2018;36:633-41. doi:10.1200/JCO.2017.75.3384
- Hellmann MD, Nathanson T, Rizvi H, *et al.* Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer. *Cancer Cell* 2018;33:843-52. doi:10.1016/j.ccell.2018.03.018
- Reuben A, Zhang J, Chiou S-H, *et al.* Comprehensive T cell repertoire characterization of non-small cell lung cancer. *Nat Commun* 2020;11:603.
- Biton J, Mansuet-Lupo A, Pécuchet N, *et al.* TP53, STK11, and EGFR mutations predict tumor immune profile and the response to Anti-PD-1 in Lung adenocarcinoma. *Clin Cancer Res* 2018;24:5710-23. doi:10.1158/1078-0432.CCR-18-0163
- Gainor JF, Shaw AT, Sequist LV, *et al.* EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis. *Clin Cancer Res* 2016;22:4585-93. doi:10.1158/1078-0432.CCR-15-3101
- Spigel DR, Reynolds C, Waterhouse D, *et al.* Phase 1/2 study of the safety and tolerability of nivolumab plus crizotinib for the first-line treatment of anaplastic lymphoma kinase translocation - positive advanced non-small cell lung cancer (CheckMate 370). *J Thorac Oncol* 2018;13:682-8. doi:10.1016/j.jtho.2018.02.022
- Mazieres J, Dilon A, Lusque A, *et al.* Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. *Ann Oncol* 2019;30:1321-8.
- Chalmers ZR, Connelly CF, Fabrizio D, *et al.* Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. *Genome Med* 2017;9:34. doi:10.1186/s13073-017-0424-2
- Gandara DR, Paul SM, Kowanetz M, *et al.* Blood-Based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. *Nat Med* 2018;24:1441-8. doi:10.1038/s41591-018-0134-3
- Dolled-Filhart M, Roach C, Toland G, *et al.* Development of a companion diagnostic for pembrolizumab in non-small cell lung cancer using immunohistochemistry for programmed death ligand-1. *Arch Pathol Lab Med* 2016;140:1243-9.
- Klein JP, Moeschberger ML. *Survival analysis: techniques for censored and truncated data*. 2nd ed. Berlin: Springer Science & Business Media, 2005.
- Zer A, Ding K, Lee SM, *et al.* Pooled analysis of the prognostic and predictive value of KRAS mutation status and mutation subtype in patients with Non-Small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. *Journal of Thoracic Oncology* 2016;11:312-23. doi:10.1016/j.jtho.2015.11.010
- Shepherd FA, Domerg C, Hainaut P, *et al.* Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. *J Clin Oncol* 2013;31:2173-81.
- Fung AS, Karimi M, Michiels S, *et al.* Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer patients. *Transl Lung Cancer Res* 2021;10:826-38.
- Tomasini P, Masciaux C, Jao K, *et al.* Effect of coexisting KRAS and TP53 mutations in patients treated with chemotherapy for non-small-cell lung cancer. *Clin Lung Cancer* 2019;20:e338-45.

- 24 Rittmeyer A, Barlesi F, Waterkamp D, *et al.* Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (oak): a phase 3, open-label, multicentre randomised controlled trial. *Lancet* 2017;389:255–65.
- 25 Hong L, Negrao MV, Dibaj SS, *et al.* Programmed Death-Ligand 1 heterogeneity and its impact on benefit from immune checkpoint inhibitors in NSCLC. *J Thorac Oncol* 2020;15:1449–59.
- 26 Jordan EJ, Kim HR, Arcila ME, *et al.* Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to Approved and emerging therapies. *Cancer Discov* 2017;7:596–609.
- 27 Le X, Negrao MV, Reuben A, *et al.* Characterization of the immune landscape of EGFR-mutant NSCLC identifies CD73/adenosine pathway as a potential therapeutic target. *J Thorac Oncol* 2021;16:583–600.
- 28 Dudnik E, Peled N, Nechushtan H, *et al.* Braf mutant lung cancer: programmed death ligand 1 expression, tumor mutational burden, microsatellite instability status, and response to immune Check-Point inhibitors. *J Thorac Oncol* 2018;13:1128–37. doi:10.1016/j.jtho.2018.04.024
- 29 Sabari JK, Leonardi GC, Shu CA, *et al.* Pd-L1 expression, tumor mutational burden, and response to immunotherapy in patients with Met exon 14 altered lung cancers. *Ann Oncol* 2018;29:2085–91.
- 30 Liu C, Peng W, Xu C, *et al.* Braf inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. *Clin Cancer Res* 2013;19:393–403.
- 31 Ebert PJR, Cheung J, Yang Y, *et al.* Map kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade. *Immunity* 2016;44:609–21. doi:10.1016/j.immuni.2016.01.024
- 32 Ascierto PA, Ferrucci PF, Fisher R, *et al.* Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. *Nat Med* 2019;25:941–6. doi:10.1038/s41591-019-0448-9
- 33 Gutzmer R, Stroyakovskiy D, Gogas H, *et al.* Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF^{V600} mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet* 2020;395:1835–44. doi:10.1016/S0140-6736(20)30934-X
- 34 Skoulidis F, Byers LA, Diao L, *et al.* Co-Occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. *Cancer Discov* 2015;5:860–77.
- 35 Arbour KC, Jordan E, Kim HR, *et al.* Effects of co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell Lung Cancer. *Clin Cancer Res* 2018;24:334–40.
- 36 Skoulidis F, Goldberg ME, Greenawalt DM, *et al.* STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant Lung adenocarcinoma. *Cancer Discov* 2018;8:822–35.
- 37 Skoulidis F, Arbour KC, Hellmann MD, *et al.* Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer. *Journal of Clinical Oncology* 2019;37:102. doi:10.1200/JCO.2019.37.15_suppl.102
- 38 Canon J, Rex K, Saiki AY, *et al.* The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. *Nature* 2019;575:217–23.
- 39 Garassino MC, Cho B-C, Kim J-H, *et al.* Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (Atlantic): an open-label, single-arm, phase 2 study. *Lancet Oncol* 2018;19:521–36. doi:10.1016/S1470-2045(18)30144-X
- 40 Lisberg A, Cummings A, Goldman JW, *et al.* A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor naïve patients with advanced NSCLC. *J Thorac Oncol* 2018;13:1138–45.
- 41 Schoenfeld AJ, Arbour KC, Rizvi H, *et al.* Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib. *Ann Oncol* 2019;30:839–44. doi:10.1093/annonc/mdz077